![](/imgs/covers/ph_cover.jpg)
|
Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613 EISSN: 0253-7613
Vol. 36, No. 3, 2004, pp. 133-139
|
Bioline Code: ph04049
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Indian Journal of Pharmacology, Vol. 36, No. 3, 2004, pp. 133-139
en |
Glycoprotein IIb/IIIa receptor and its inhibition: A platelet-directed therapeutic strategy
Shah HD, Goyal RK
Abstract
Platelets play a key role in atherosclerosis, thrombosis and acute coronary syndromes. Drugs that dissolve blood clot (thrombolytic agents) and that prevent clot propagation (antiplatelet and anticoagulant agents) are used to treat a broad array of cardiovascular diseases. Therapeutic manipulation of platelet function has focused principally on the use of aspirin which has proved effective in many clinical situations, despite its relatively weak antiplatelet action as compared to newer agents like ticlopidine, clopidogrel and more recently, platelet glycoprotein (GP) IIb/IIIa receptor inhibitors. The platelet GP IIb/IIIa receptor has been identified as a pivotal mediator of platelet aggregation, making it a logical target for the control of the platelet response to vascular injury. The primary mechanism of GP IIb/IIIa antagonists is the inhibition of the final common pathway of platelet aggregation: fibrinogen binding to the GP IIb/IIIa complex. Various antagonists of the GP IIb/IIIa receptor are currently receiving considerable attention and are being investigated for various clinical settings including angina, myocardial infarction and interventional cardiology.
Keywords
Antiplatelet agents, antithrombotics, coronary artery disease, glycoprotein IIb/IIIa antagonists
|
|
© Copyright 2004 Indian Journal of Pharmacology. Alternative site location: http://www.ijp-online.com
|
|